Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Calcitonin Therapy for Bone Disease and Hypercalcemia

Calcitonin Therapy for Bone Disease and Hypercalcemia Abstract Since a "hypocalcemic substance" (ie, calcitonin) was first demonstrated in extracts of rat thyroid tissue by Hirsch et al1 in 1963, its role in maintaining mineral homeostasis has undergone extensive analyses. Mechanisms that regulate the secretion and the biological activity of calcitonin in healthy humans, patients with medullary carcinoma, and in lower animal species have been defined, and the sequence for the 32—amino acid calcitonin peptide isolated from human, bovine, ovine, salmon, and porcine thyroid glands established.2,3 Despite these many observations, which stem primarily from a combination of in vitro experiments on thyroid or ultimobranchial tissue, in situ perfusions of the thyroid gland of pigs, goats, cows, and dogs, and in vivo studies in rats following a multitude of dietary pertubations,2,4 the functional role of calcitonin in either conditioning or regulation mineral and skeletal metabolism in healthy humans is still conjectural at best. Women have lower basal References 1. Hirsch PF, Gauthier GF, Munson PL: Thyroid hypocalcemic principle and recurrent laryngeal nerve injury as factors affecting the response to parathyroidectomy in rats. Endocrinology 1963; 73:244-252.Crossref 2. Avioli LV: What's new in endocrinology—calcitonin , in Ingbar SH (ed): The Year in Endocrinology . New York, Plenum Publishing Corp, 1976, pp 233-248. 3. Silva OL, Snider RH, Becker KL: Radioimmunoassay of calcitonin in human plasma. Clin Chem 1974;20:337-339. 4. Care AD, Bates RFL, Swaminathan K: The control of parathyroid hormone and calcitonin secretion and their interaction with other endocrine systems , in Talmage RV, Owen M, Parsons JA (eds): Calcium Regulating Hormones . Amsterdam, Excerpta Medica, 1975, pp 100-110. 5. Heath H, Sizemore GW: Plasma calcitonin in normal man: Differences between men and women. J Clin Invest 1977;60:1135-1140.Crossref 6. Parthemore JG, Deftos LJ: Calcitonin secretion in normal human subjects. J Clin Endocrinol Metabol 1978;47:184-188.Crossref 7. Stevenson JC, Hillyard CJ, Abeyasekera J, et al: Calcitonins and the calcium-regulating hormones in postmenopausal women: Effect of estrogen. Lancet 1981;1:693-695.Crossref 8. Singer FR, Schiller AL, Pyle EB, et al: Paget's disease of bone , in Avioli LV, Krane SM (eds): Metabolic Bone Disease . New York, Academic Press Inc, 1978, vol 2, pp 489-575. 9. Fillastri JP, Humbert G, Leroy J, et al: Furosemide, mithramycin and salmon calcitonin in hypercalcemia. Eur J Intensive Care Med 1975;1:185-188.Crossref 10. Hosking DJ: Treatment of severe hypercalcemia with calcitonin. Metabol Bone Dis Relat Res 1980;2:207-212.Crossref 11. Agrawal R, Wallach S, Cohn S, et al: Calcitonin treatment of osteoporosis , in Pecile A (ed): Calcitonin 1980 . Amsterdam, Excerpta Medica, 1981, pp 237-245. 12. Chesnut CH, Baylink DJ, Roos BA, et al: Calcitonin and postmenopausal osteoporosis , in Pecile E (ed): Calcitonin 1980 . Amsterdam, Excerpta Medica, 1981, pp 247-255. 13. Virgo P, Columbo B, Verdoia C, et al: Recent progress in the treatment of postmenopausal and senile osteoporosis , in Pecile E (ed): Calcitonin 1980 . Amsterdam, Excerpta Medica, 1981, pp 256-268. 14. Wallach S, Cohn SH, Atkins HL, et al: Effect of calcitonin on skeletal mass in osteoporosis. Clin Ther Res 1977;22:556-572. 15. Krane SM, Harris ED Jr, Singer FR, et al: Acute effects of calcitonin on bone formation in man. Metabolism 1973;22:51-58.Crossref 16. Nagant de Deuxchaisnes C, Rombouts-Lindemans C, Huaax JP, et al: Roentgenologic evaluation of the diphosphonate EHDP and of combined therapy (EHDP and calcitonin) in Paget's disease of bone , in MacIntyre I, Selks H (eds): Molecular Endocrinology . New York, Elsevier-North Holland Inc, 1979, pp 405-433. 17. Krane SM: Etidronate disodium in the treatment of Paget's disease of bone. Ann Intern Med 1982;96:619-625.Crossref 18. Douglas DL, Russell RGG, Preston CJ, et al: Effect of dichloromethylene diphosphonate in Paget's disease of bone and in hypercalcemia due to primary hyperparathyroidism or malignant disease. Lancet 1980;1:1043-1047.Crossref 19. Delmas PD, Chapry MC, Vignon E, et al: Long-term effects of dichloromethylene diphosphonate in Paget's disease of bone. J Clin Endocrinol Metabol 1982;54:837-844.Crossref 20. Haddad JG, Caldwell JG: Calcitonin resistance: Clinical and immunologic studies in subjects with Paget's disease of bone treated with porcine and salmon calcitonin. J Clin Invest 1972; 51:3133-3141.Crossref 21. De Rose J, Singer FR, Avramides A, et al: Response of Paget's disease to porcine and salmon calcitonins. Am J Med 1974;56:858-866.Crossref 22. Singer FR, Ahrne-Collier I: Salmon calcitonin therapy: Antibodies and clinical resistance in patients with Paget's disease of bone , in MacIntyre I, Szelke M (eds): Molecular Endocrinology . New York, Elsevier-North Holland Inc, 1977, pp 207-212. 23. Bijvoet OLM, Van der Sluys Veer J, Jansen AP: Effects of calcitonin on patients with Paget's disease, thyrotoxicosis or hypercalcemia. Lancet 1968;1:876-881.Crossref 24. Sjoberg HK, Hjern B: Acute treatment with calcitonin in primary hyperparathyroidism and hypercalcemia of other origin. Acta Chir Scand 1975;141:90-94. 25. Vaughn CD, Vaitkevicius VK: The effect of calcitonin in hypercalcemia in patients with malignancy. Cancer 1974;34:1268-1274.Crossref 26. Wisneski LA, Croom WP, Silva OL, et al: Salmon calcitonin in hypercalcemia. Clin Pharmacol Ther 1978;23:219-226. 27. Pezeshki C, Brooker AF: Immobilization hypercalcemia: Report of two cases treated with calcitonin. J Bone Joint Surg Am 1977;59:971-975. 28. Binstock ML, Mundy GR: Effect of calcitonin and glucocorticoids in combination with the hypercalcemia of malignancy. Ann Intern Med 1980;93:269-272.Crossref 29. DeFronzo RA, Cooke CR, Wright JR, et al: Renal function in patients with multiple myeloma. Medicine 1978;57:151-166.Crossref 30. Aldinger KA, Samaan NA: Hypokalemia with hypercalcemia. Ann Intern Med 1977;87:571-573.Crossref 31. Shackney S, Hasson J: Precipitous fall in serum calcium, hypotension, and acute renal failure after intravenous phosphate therapy for hypercalcemia: Report of two cases. Ann Intern Med 1967;66:909-916.Crossref 32. Gennari C: Calcitonin and bone metastases of cancer , in Pecile A (ed): Calcitonin 1980 . Amsterdam, Excerpta Medica, 1981, pp 277-287. 33. Recker RP, Savile PD, Heaney RP: Effect of estrogens and calcium carbonate on bone loss in postmenopausal women. Ann Intern Med 1977;87:649-655.Crossref 34. Thompson JS, Palmieri GMA, Eliel LP, et al: Effect of porcine calcitonin on osteoporosis induced by adrenal cortical steroids. J Bone Joint Surg Am 1972;54:1490-1500. 35. Casio VL, Adani S, Avioli LV, et al: Suppressive effect of chronic glucocorticoid treatment on circulating calcitonin in man. Calcif Tissue Int 1982;34:309-311.Crossref 36. Hahn TJ, Boisseau VC, Avioli LV: Effect of chronic corticosteroid administration on diaphyseal and metaphyseal bone mass. J Clin Endocrinol Metabol 1974;38:274-282.Crossref 37. Feletti C, Bonomini V: Effect of calcitonin on bone lesions in chronic dialysis patients. Nephron 1979;24:85-88.Crossref 38. Feletti C, Docci D, Capelli M, et al: Pathophysiology of endogenous calcitonin in chronic uremia. Min Elect Metabol 1981; 6:174-181. 39. Heynen G, Kanis JA, Oliver D, et al: Evidence that endogenous calcitonin protects against renal bone disease. Lancet 1976;1:1322-1325.Crossref 40. Kanis JA, Earnshaw M, Heynen G, et al: Changes in histologic and biochemical indexes of bone turnover after bilateral nephrectomy in patients on hemodialysis. N Engl J Med 1977;296:1073-1079.Crossref 41. Parkinson IS, Ward MK, Feist TC, et al: Fracturing dialysis osteodystrophy and dialysis encephalopathy. Lancet 1979;1:406-408.Crossref http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Archives of Internal Medicine American Medical Association

Calcitonin Therapy for Bone Disease and Hypercalcemia

Archives of Internal Medicine , Volume 142 (12) – Nov 1, 1982

Loading next page...
 
/lp/american-medical-association/calcitonin-therapy-for-bone-disease-and-hypercalcemia-ude9RyAXJf
Publisher
American Medical Association
Copyright
Copyright © 1982 American Medical Association. All Rights Reserved.
ISSN
0003-9926
eISSN
1538-3679
DOI
10.1001/archinte.1982.00340250034005
Publisher site
See Article on Publisher Site

Abstract

Abstract Since a "hypocalcemic substance" (ie, calcitonin) was first demonstrated in extracts of rat thyroid tissue by Hirsch et al1 in 1963, its role in maintaining mineral homeostasis has undergone extensive analyses. Mechanisms that regulate the secretion and the biological activity of calcitonin in healthy humans, patients with medullary carcinoma, and in lower animal species have been defined, and the sequence for the 32—amino acid calcitonin peptide isolated from human, bovine, ovine, salmon, and porcine thyroid glands established.2,3 Despite these many observations, which stem primarily from a combination of in vitro experiments on thyroid or ultimobranchial tissue, in situ perfusions of the thyroid gland of pigs, goats, cows, and dogs, and in vivo studies in rats following a multitude of dietary pertubations,2,4 the functional role of calcitonin in either conditioning or regulation mineral and skeletal metabolism in healthy humans is still conjectural at best. Women have lower basal References 1. Hirsch PF, Gauthier GF, Munson PL: Thyroid hypocalcemic principle and recurrent laryngeal nerve injury as factors affecting the response to parathyroidectomy in rats. Endocrinology 1963; 73:244-252.Crossref 2. Avioli LV: What's new in endocrinology—calcitonin , in Ingbar SH (ed): The Year in Endocrinology . New York, Plenum Publishing Corp, 1976, pp 233-248. 3. Silva OL, Snider RH, Becker KL: Radioimmunoassay of calcitonin in human plasma. Clin Chem 1974;20:337-339. 4. Care AD, Bates RFL, Swaminathan K: The control of parathyroid hormone and calcitonin secretion and their interaction with other endocrine systems , in Talmage RV, Owen M, Parsons JA (eds): Calcium Regulating Hormones . Amsterdam, Excerpta Medica, 1975, pp 100-110. 5. Heath H, Sizemore GW: Plasma calcitonin in normal man: Differences between men and women. J Clin Invest 1977;60:1135-1140.Crossref 6. Parthemore JG, Deftos LJ: Calcitonin secretion in normal human subjects. J Clin Endocrinol Metabol 1978;47:184-188.Crossref 7. Stevenson JC, Hillyard CJ, Abeyasekera J, et al: Calcitonins and the calcium-regulating hormones in postmenopausal women: Effect of estrogen. Lancet 1981;1:693-695.Crossref 8. Singer FR, Schiller AL, Pyle EB, et al: Paget's disease of bone , in Avioli LV, Krane SM (eds): Metabolic Bone Disease . New York, Academic Press Inc, 1978, vol 2, pp 489-575. 9. Fillastri JP, Humbert G, Leroy J, et al: Furosemide, mithramycin and salmon calcitonin in hypercalcemia. Eur J Intensive Care Med 1975;1:185-188.Crossref 10. Hosking DJ: Treatment of severe hypercalcemia with calcitonin. Metabol Bone Dis Relat Res 1980;2:207-212.Crossref 11. Agrawal R, Wallach S, Cohn S, et al: Calcitonin treatment of osteoporosis , in Pecile A (ed): Calcitonin 1980 . Amsterdam, Excerpta Medica, 1981, pp 237-245. 12. Chesnut CH, Baylink DJ, Roos BA, et al: Calcitonin and postmenopausal osteoporosis , in Pecile E (ed): Calcitonin 1980 . Amsterdam, Excerpta Medica, 1981, pp 247-255. 13. Virgo P, Columbo B, Verdoia C, et al: Recent progress in the treatment of postmenopausal and senile osteoporosis , in Pecile E (ed): Calcitonin 1980 . Amsterdam, Excerpta Medica, 1981, pp 256-268. 14. Wallach S, Cohn SH, Atkins HL, et al: Effect of calcitonin on skeletal mass in osteoporosis. Clin Ther Res 1977;22:556-572. 15. Krane SM, Harris ED Jr, Singer FR, et al: Acute effects of calcitonin on bone formation in man. Metabolism 1973;22:51-58.Crossref 16. Nagant de Deuxchaisnes C, Rombouts-Lindemans C, Huaax JP, et al: Roentgenologic evaluation of the diphosphonate EHDP and of combined therapy (EHDP and calcitonin) in Paget's disease of bone , in MacIntyre I, Selks H (eds): Molecular Endocrinology . New York, Elsevier-North Holland Inc, 1979, pp 405-433. 17. Krane SM: Etidronate disodium in the treatment of Paget's disease of bone. Ann Intern Med 1982;96:619-625.Crossref 18. Douglas DL, Russell RGG, Preston CJ, et al: Effect of dichloromethylene diphosphonate in Paget's disease of bone and in hypercalcemia due to primary hyperparathyroidism or malignant disease. Lancet 1980;1:1043-1047.Crossref 19. Delmas PD, Chapry MC, Vignon E, et al: Long-term effects of dichloromethylene diphosphonate in Paget's disease of bone. J Clin Endocrinol Metabol 1982;54:837-844.Crossref 20. Haddad JG, Caldwell JG: Calcitonin resistance: Clinical and immunologic studies in subjects with Paget's disease of bone treated with porcine and salmon calcitonin. J Clin Invest 1972; 51:3133-3141.Crossref 21. De Rose J, Singer FR, Avramides A, et al: Response of Paget's disease to porcine and salmon calcitonins. Am J Med 1974;56:858-866.Crossref 22. Singer FR, Ahrne-Collier I: Salmon calcitonin therapy: Antibodies and clinical resistance in patients with Paget's disease of bone , in MacIntyre I, Szelke M (eds): Molecular Endocrinology . New York, Elsevier-North Holland Inc, 1977, pp 207-212. 23. Bijvoet OLM, Van der Sluys Veer J, Jansen AP: Effects of calcitonin on patients with Paget's disease, thyrotoxicosis or hypercalcemia. Lancet 1968;1:876-881.Crossref 24. Sjoberg HK, Hjern B: Acute treatment with calcitonin in primary hyperparathyroidism and hypercalcemia of other origin. Acta Chir Scand 1975;141:90-94. 25. Vaughn CD, Vaitkevicius VK: The effect of calcitonin in hypercalcemia in patients with malignancy. Cancer 1974;34:1268-1274.Crossref 26. Wisneski LA, Croom WP, Silva OL, et al: Salmon calcitonin in hypercalcemia. Clin Pharmacol Ther 1978;23:219-226. 27. Pezeshki C, Brooker AF: Immobilization hypercalcemia: Report of two cases treated with calcitonin. J Bone Joint Surg Am 1977;59:971-975. 28. Binstock ML, Mundy GR: Effect of calcitonin and glucocorticoids in combination with the hypercalcemia of malignancy. Ann Intern Med 1980;93:269-272.Crossref 29. DeFronzo RA, Cooke CR, Wright JR, et al: Renal function in patients with multiple myeloma. Medicine 1978;57:151-166.Crossref 30. Aldinger KA, Samaan NA: Hypokalemia with hypercalcemia. Ann Intern Med 1977;87:571-573.Crossref 31. Shackney S, Hasson J: Precipitous fall in serum calcium, hypotension, and acute renal failure after intravenous phosphate therapy for hypercalcemia: Report of two cases. Ann Intern Med 1967;66:909-916.Crossref 32. Gennari C: Calcitonin and bone metastases of cancer , in Pecile A (ed): Calcitonin 1980 . Amsterdam, Excerpta Medica, 1981, pp 277-287. 33. Recker RP, Savile PD, Heaney RP: Effect of estrogens and calcium carbonate on bone loss in postmenopausal women. Ann Intern Med 1977;87:649-655.Crossref 34. Thompson JS, Palmieri GMA, Eliel LP, et al: Effect of porcine calcitonin on osteoporosis induced by adrenal cortical steroids. J Bone Joint Surg Am 1972;54:1490-1500. 35. Casio VL, Adani S, Avioli LV, et al: Suppressive effect of chronic glucocorticoid treatment on circulating calcitonin in man. Calcif Tissue Int 1982;34:309-311.Crossref 36. Hahn TJ, Boisseau VC, Avioli LV: Effect of chronic corticosteroid administration on diaphyseal and metaphyseal bone mass. J Clin Endocrinol Metabol 1974;38:274-282.Crossref 37. Feletti C, Bonomini V: Effect of calcitonin on bone lesions in chronic dialysis patients. Nephron 1979;24:85-88.Crossref 38. Feletti C, Docci D, Capelli M, et al: Pathophysiology of endogenous calcitonin in chronic uremia. Min Elect Metabol 1981; 6:174-181. 39. Heynen G, Kanis JA, Oliver D, et al: Evidence that endogenous calcitonin protects against renal bone disease. Lancet 1976;1:1322-1325.Crossref 40. Kanis JA, Earnshaw M, Heynen G, et al: Changes in histologic and biochemical indexes of bone turnover after bilateral nephrectomy in patients on hemodialysis. N Engl J Med 1977;296:1073-1079.Crossref 41. Parkinson IS, Ward MK, Feist TC, et al: Fracturing dialysis osteodystrophy and dialysis encephalopathy. Lancet 1979;1:406-408.Crossref

Journal

Archives of Internal MedicineAmerican Medical Association

Published: Nov 1, 1982

References